Background/Aims: Astrocytes are critical for the development of postoperative cognitive dysfunction (POCD). In addition, astrocytes express toll-like receptors 4 (TLR4) and build up responses to innate immune triggers by releasing pro-inflammatory molecules. The pathogenesis of neurological disorders often involves the activation of astrocytes and associated inflammatory processes. Lithium, a primary drug for the treatment of bipolar disorder, has recently been suggested to have a role in neuroprotection during neurodegenerative diseases. In this study, we aimed to investigate whether lithium can ameliorate LPS-induced astrocytes activation via inhibition of TLR4 expression. Methods: Primary astrocytes cells were pretreated with lithium and stimulated with lipopolysaccharide (LPS). Cellular activation, cytokine production, and TLR4 expression, were assessed. Results: Lithium significantly inhibited LPS-induced astrocytes activation and pro-inflammatory cytokine production, as well as LPS-induced TLR4 expression. Conclusions: Lithium can inhibit LPS-induced TLR4 expression and astrocytes activation. These results indicate that lithium plays an important role in astrocytes activation and neuroinflammation-related diseases, which may open new avenues for neuroscience and biomedical research, and also offers new insight into the treatment of POCD.
0111:B4) were purchased from Sigma-Aldrich (St. Louis, MO, USA). LY294002, WST-8 dye, RIPA buffer and the BCA kit were purchased from Beyotime (Shanghai, China). The rabbit anti-GFAP polyclonal antibody (a marker for glial fibrillary acidic protein) was purchased from Cell Signaling Technolgy (Boston, MA, USA). Fluoroshield mounting medium with 4, 6-diamidino-2-phenylindole (DAPI) was purchased from Abcam (Hongkong, China). Rat IL-6 Immunoassay Kit and Rat TNF-α Immunoassay Kit were obtained from R&D Systems, Inc. (Minneapolis, MN, USA). The TLR4 monoclonal antibody was purchased from Abcam (Hongkong, China). GAPDH was purchased from Bioworld Technology, Inc. (USA), secondary anti-rabbit and anti-mouse antibodies were all purchased from Jackson Immuno Research Laboratories Inc. (Boston, MA, USA). FITC-conjugated goat anti-rabbit IgG and PE-conjugated goat anti-mouse antibodies were purchased from BD (BD Bioscience, USA).
Astrocyte-enriched cultures
Primary rat astrocytes cells were prepared as described in a previous protocol, with slight modifications [19] . Briefly, whole brains were isolated from rat at postnatal day one to two. The meninges and blood vessels were removed completely in cold D-Hank's buffered saline. Next, the brains were minced with sterile scissors and digested with 0.25% Trypsin-EDTA solution for 10 minutes at 37°C. The trypsinization was stopped by adding an equal volume of culture medium, which was high-glucose DMEM containing 10% FBS and penicillin (100 U/ml)/streptomycin (100 µg/ml). The dissociated cells were passed through a 100-um pore mesh, pelleted at 1,500 rpm for 5 minutes, and re-suspended in culture medium. The cells were seeded on poly-D-lysine pre-coated cell culture flasks and cultured at 37°C in a humidified atmosphere of 5% CO2/95% air. The medium was replaced every three to four days after seeding. After the glial cells formed a confluent monolayer (10-14 days), the astrocytes cells were separated from the microglia by shaking for 5 hours at 150 rpm and seeded into 4-well culture plates at a density of 10x5 cells/cm. Cultures were passaged every 2 weeks into new 10 cm dishes at least 3 times (=G3) to achieve highly pure astrocytes cultures [20, 21] . The cells were starved overnight and then subjected to treatments. Culture purity was > 95% determined by GFAP. The cells were pretreated with lithium (1 mM) for 30minutes before LPS (100 ng/ml)) simulation.
Cell viability 2-(2-Methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium Sodium Salt (WST-8) is better than 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) for analyzing cell viability, because it can be reduced to soluble formazan by dehydrogenase in the mitochondria and has low cytotoxicity. The cell viability was measured using the WST-8 dye according to the manufacturer's instructions. Briefly, the astrocytes cells were seeded into 96-well plates at a density of 3 × 10 4 cells/well. Following this treatment, the WST-8 dye was added to each well, then the cells were incubated at 37°C for 2 hours and the absorbance was determined at 450 nm using a microplate reader.
TNF-α and IL-6 assay
The amount of TNF-α and IL-6 in the culture medium was measured with a commercial ELISA kit from R&D Systems.
Western blotting
Cellular proteins were extracted from the primary astrocytes cells using RIPA buffer. The protein concentration in the supernatant fluid of the lysate was measured using a BCA kit. Proteins (50 μg) in the cell extracts were denatured with sodium dodecyl sulfate (SDS) sample buffer and separated using 10% SDS-polyacrylamide gel electrophoresis (PAGE). The proteins were transferred to a polyvinylidene fluoride (PVDF) microporous membrane (Millipore, Bedford, MA, USA), which was then blocked with 5% skim milk for one hour at room temperature. The membrane was incubated with primary antibody overnight at 4°C. The following primary anti-bodies were used: mouse monoclonal anti-TLR4 (Abcam, number: 22048, 1:1000), rabbit monoclonal anti-GFAP (CST, number: #12389p, 1:1000), mouse monoclonal anti-GAPDH (Bioworld Technology lnc. number: Ap0063, 1:1000). After adding the anti-rabbit or anti-mouse secondary antibody (Jackson Immuno Research Laboratories INC. number: 122825 and 122627, 1:1000) for 1 hour, the protein bands on the membranes were detected with an enhanced chemiluminescence kit.
Immunofluorescence
To determine the activation of the astrocytes, the cells were fixed with 4% paraformaldehyde for 30 minutes; non-specific binding was blocked by incubating cells in a 5% BSA and 0.1% Triton X-100 solution for 1 hour at room temperature. The astrocytes cells were incubated with rabbit anti-GFAP polyclonal antibody (1:200) and mouse anti-TLR4 (1:100) monoclonal antibody in the blocking solution overnight at 4°C. After three washes with PBS, the astrocytes cells were incubated with the corresponding FITCconjugated goat anti-rabbit IgG (1:200) and PE-conjugated goat anti-mouse IgG (1:200) for 2 hours at room temperature and the nuclei were stained with DAPI. Fluorescent images were acquired using a confocal microscope.
RNAi transfection
The primary astrocytes cells were transfected under serum-free conditions with TLR4 siRNA (100 nM) or control siRNA sequences using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Primers are listed as the following: forward, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and reverse 5'-ACG UGA CAC GUU CGG AGA ATT-3'. Eight hours later, the medium was replaced with regular culture medium containing serum, and the incubation was continued for 48 hours at 37°C before the assays were performed.
RNA purification and Real-time PCR
Total RNA was extracted from primary astrocytes cell cultures using Trizol Reagent (Invitrogen), and reverse transcription was performed from 1 µg of total RNA for each sample using the Transcription First Strand cDNA Synthesis Kits (Roche) according to the manufacturer's instructions. Real-time PCR amplification was performed using StepOne Plus Real-Time PCR System (Applied Biosystems) with the SYBR Green master mix (Applied Biosystems, Foster City, CA) in a final volume of 10µg that contained 1µg cDNA template from each sample. Primers are listed as the following: rat GAPDH forward, 5'-GGG TGT GAA CCA CGA GAAAT-3', and reverse, 5'-CCA CAG TCT TCT GAG TGG CA-3'; rat GFAP forward, 5'-GGT GGA GAG GGA CAA TCTCA-3', and reverse, 5'-CCA GCT GCT CCT GGA GTTCT-3'; rat TLR4 forward, 5'-GGG GCA ACC GCT GGG AGAGA-3', and reverse, 5'-AAC CAG CGG AGG CCG TGAGA-3'. The cycling conditions were 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The relative mRNA values were normalized to the GAPDH gene control values and calculated using the comparative cycle threshold (△△Ct) method.
Statistical analysis
All experimental results were from at least three separate experiments. The data were represented as the mean ± SD. The significance of the difference between the control and samples treated with various compounds was determined by one-way ANOVA followed by the post-hoc least significant difference test. The differences were considered significant at P < 0.05.
Results

Effects of lithium and LPS on cell viability in astrocytes
WST-8 assay was used to evaluate the toxic effects of lithium and/or LPS on astrocytes. The astrocytes cells were incubated with lithium (0.1, 0.3, 1.0 and 3.0 mM) and/or LPS (100 ng/ml) for 24 hours, and then cell viability was detected by WST-8 assay. Our results indicate that lithium (1.0 mM) and 100 ng/ml LPS exerted no obvious toxic effects on astrocytes (Fig.  1) .
Lithium inhibits LPS-induced astrocytes activation
Activated astrocytes were detected with expression levels of GFAP. The astrocytes were pretreated with lithium (1.0 mM) for 30 minutes and then stimulated with LPS (100 ng/ml) for 24 hours. As shown in Fig. 2A , compared with the control group, lithium significantly inhibited the LPS-mediated up-regulated m RNA expression levels of GFAP. Western blot also showed that when pretreated with lithium 30 min before LPS application, the level of GFAP Fig. 1 . The effects of lithium and lipopolysaccharide (LPS) on cell viability in primary astrocytes. The astrocytes cells were exposed to different concentrations of lithium (0.1, 0.3, 1, and 3 mM) with and without LPS (100 ng/ml) for 24 hours. Cell viability was determined using a colorimetric method. Each data point represents the mean ± SD. of at least three separate experiments in which treatments were performed in quadruplicates. Western blotting analysis of GFAP levels, the levels of GFAP were quantified and normalized to the respective GAPDH. Each value was then expressed relative to the one treated with medium, which was set as 1. ** P < 0.01 versus the response to medium alone, ## P < 0.01 versus LPS treatment groups. The data are presented as the mean ± SD. of three independent experiments. (C) The cells were stained with GFAP antibody and unregulated GFAP-immunopositive expression (green) on the activated astrocytes was observed using confocal scanning. The blue staining represents DAPI. Scale bar 25 μm.
Lithium down-regulates the production of IL-6 and TNF-α by LPS-induced astrocytes
Astrocytes-mediated neuroinflammation occurs primarily due to the excessive proinflammatory mediators and cytotoxic factors released from activated astrocytes and their downstream signaling cascades. Levels of pro-inflammatory mediators were determined in the present study. As shown in Fig. 3 , following the incubation with LPS at 100 ng/ml for 24 hours, the production of IL-6 and TNF-α from primary astrocytes cells obviously increased via the control respectively. Pre-incubation with lithium (1.0 mM) for 30 minutes partially abolished LPS-induced IL-6 and TNF-α release, suggesting that lithium can downregulate LPS-induced production of inflammatory factors.
TLR4 regulates astrocytes activation
To further ascertain whether TLR4 was involved in LPS-induced astrocyte activation, we transfected astrocytes with TLR4 siRNA. After 48 hours, the TLR4-specific siRNA could obviously down-regulate the TLR4 protein, as shown in Fig. 4B . Meanwhile, we also found that TLR4 siRNA down-regulate the level of GFAP remarkably induced by LPS (Fig. 4C) . As shown in Fig. 4D and 4E, the TLR4-specific siRNA could inhibit IL-6 and TNF-α released from the LPS-stimulated astrocytes. Similarly, the GFAP expression (in green) was significantly down-regulated by the TLR4-specific siRNA (Fig. 4A) . These results indicate that TLR4 participate in astrocytes activation and inflammatory response.
The effect of Lithium on TLR4 in astrocytes
To examine TLR4 distribution in astrocytes, we did double staining of TLR4 with GFAP. As shown in Fig. 5A , we observed that lithium significantly inhibited the TLR4 expression induced by LPS. Consistent with the above phenomenon, the level of GFAP was markedly decreased by lithium. As shown in Fig. 5C , treatment of astrocytes with LPS resulted in an increased expression of TLR4, while this consequence could be supressed by lithium. Similarly, lithium relieved the mRNA expression level of TLR4 induced by LPS (Fig. 5B) . Taken all together, these data indicate that the inhibitory effect of lithium on astrocytes activation is partly via suppression of TLR4 expression.
in models of acute injuries [9] . While little is known about the mechanism of lithium-mediated inhibition of astrocytes activation, we have demonstrated here in that lithium ameliorates LPS-induced astrocytes activation by activating TLR4.
Accounting for nearly half of the cells in the human brain, astrocytes are responsible for a series of complex and essential functions in the healthy CNS, including primary roles in synaptic transmission and information processing by neural circuits, which are also considered to participate in almost all CNS disease [27, 28] . As above, several experiments have shown that microglia and astrocytes are involved in sustained inflammatory responses in animal models of neurodegeneration [29] . Microglia cells are mainly activated in the initial phase after minor surgery [30] , whereas the activation of astrocytes persists into the final periods in rats with bilateral common carotid artery occlusion. Furthermore, astrocytes play a key role in modulating the immune responses of the CNS to infections or disease [12] . In both microglia and astrocytes, TLR4 mediate α-SYN induction of TNF-α and IL-6 and α-SYN can activate extracellular pro-inflammatory TLR4 pathways in astrocytes [31, 32] . However, the specific mechanisms of astrocytes activation, such as their responses to TLR4 after the treatment of lithium, remain highly unclear. For this reason, we designed the present study. Given astrocytes reactivity was originally characterized by morphological changes (hypertrophy, remodeling processes) and the overexpression of the intermediate filament Each value was then expressed relative to the one treated with medium, which was set as 1. ** P < 0.01 versus the response to medium alone. ## P < 0.01 versus the LPS treatment groups. The data are presented as the mean ± SD. of three independent experiments. GFAP, we examined the level of GFAP to evaluate the activity of astrocytes and found that lithium could not only inhibit LPS-stimulated activation of primary astrocytes (Fig. 2) , but also reduce IL-6 and TNF-α production from activated astrocytes (Fig. 3) .
TLR4, a receptor of LPS, serves as the primary mediator of innate immune responses to pathogens by activating a cascade of pro-inflammatory events [33] . The activation of TLR4 by LPS triggers signaling via downstream signaling factors such as adaptor myeloid differentiation protein 88 (MyD88), leading to the activation of NF-κB and ultimately inducing the expression of inflammation-related genes [34] . Thus, the inhibition of TLR4 signaling can reduce pro-inflammatory downstream signaling pathways by suppressing target gene expression and cellular responses. It has been shown that inhibiting TLR4 expression can suppress LPS-stimulated production of IL-β and TNF-α in the BV-2 microglia cell line [35] . Our previous studies have confirmed the role of TLR4 in microglia activation clearly [26, 36] , but the precise effect of TLR4 on astrocytes activation remains to be elucidated. Recent data has showed that after TLR4 activation, astrocytes may cause alterations on the blood brain barrier (BBB), promote inflammation, and modulate immune responses [14] . In agreement with this finding, we found that LPS could stimulate activation of primary astrocytes and TLR4 expression, while pretreatment with TLR4 siRNA could inhibit this phenomenon (Fig. 4A , B and C), suggesting that TLR4 was involved in astrocytes activation and the resulting cytokine production ( Fig. 4D and E) . Consistent with the above results, we noticed that lithium remarkably alleviated the expression of TLR4 (Fig. 5) . Combination of the above experimental results, it is suggested that lithium ameliorates LPS-induced astrocytes activation partly via inhibition of TLR4 expression. The activation of TLR4 in astrocytes induces signaling through NF-κB, MAPK, and JAK1/STAT1 pathways, which in turn regulate the expression of a wide range of proinflammatory molecules [14] . Nevertheless, whether lithium plays a role in the activation of TLR4 in astrocytes via these signal pathways needs further study.
Lithium, an established drug used in the treatment of bipolar disorder, has a neuroprotective effect. And intracellular signaling systems involved in neuroprotection are an important target for lithium's mood stabilizing and neuroprotective effects, as shown in previous research [37] . It's worth noting that lithium may actually slow the progression of cognitive and functional deficits in patients with amnestic mild cognitive impairment [38] . In addition, recent studies in vivo showed that the anti-inflammatory effects of lithium have been confirmed, and these effects are concerned with the inhibition of microglial activation and attenuating the overexpression of proinflammatory cytokines and chemokines [18, 25] . There are several findings that support the notion that astrocytes may also be an important target of lithium action in the brain [39] . But little is known about the effect of lithium on astrocytes and the involvement of TLR4. Hence, we hypothesized that lithium could inhibit LPS-induced up-regulation of TLR4 in astrocytes, which may participate in the neuroinflammatory response. Treatment of cultures with TLR4 ligands has become a popular approach to investigate astrocytes neuroinflammatory responses and to simulate the neural environment in various CNS disorders. In this study, we used LPS as a ligand to investigate the role of TLR4 in astrocytes on inflammation in vitro, and found that in primary astrocytes, LPS increased TLR4 expression and astrocytes activation, while this phenomenon is reversed by lithium. In accordance with the effect of TLR4 siRNA, LPS-induced production of TNF-α and IL-6 were also significantly depressed by lithium, revealing that lithium could ameliorate LPS-induced astrocytes activation via the TLR4 pathway. Our study provides new information on the potential neuroprotective effect of lithium. The method of effectively suppressing the TLR4-mediated inflammatory signaling pathway in astrocytes might be the key target for drug screening to treat CNS disease. The originality of this manuscript consists in showing in vitro data on the potential role of lithium in inhibiting LPS-induced TLR4 and inflammatory cytokines in primary astrocytes. It should be noted that the concentrations of lithium and LPS in vivo do not need to reach the levels required in vitro to observe the antiinflammatory and pro-inflammatory effects. This is a limitation of all in vitro work, which must be carried out at supra-pharmacological concentrations. 
